Novo Nordisk A/S $NVO Stock Sold by Smith Chas P & Associates PA Cpas

Posted by Stanley Muller on Oct 22nd, 2026

Smith Chas P & Associates PA Cpas cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 99.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,452 shares of the company’s stock after selling 943,699 shares during the period. Smith Chas P & Associates PA Cpas’ holdings in Novo Nordisk A/S were worth $251,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $287,660,000. State Street Corp boosted its position in Novo Nordisk A/S by 0.6% during the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after buying an additional 32,641 shares during the period. Royal Bank of Canada grew its holdings in Novo Nordisk A/S by 3.2% in the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after acquiring an additional 141,376 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after purchasing an additional 71,684 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Novo Nordisk A/S by 6.7% in the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: CagriSema produced an average 25% reduction in body weight after 68 weeks among women with obesity or overweight in a late-stage analysis. The result strengthens the drug’s potential as a successor to Wegovy and could improve Novo’s long-term position in the expanding obesity-treatment market. Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Positive Sentiment: The CagriSema data prompted a recent rally as investors viewed the treatment’s efficacy as a potential catalyst for renewed growth. Regulatory submissions and further clinical progress could provide additional upside, although approval is not yet guaranteed. Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
Positive Sentiment: Novo expanded its 2026 share buyback, increasing its treasury-share stake to 1.2%. The program signals management’s confidence and may support earnings per share by reducing the number of shares outstanding. Novo Nordisk expands 2026 share buyback
Neutral Sentiment: Novo remains a major player in diabetes and obesity treatments, with additional pipeline projects and partnerships offering potential growth over the next decade. However, those benefits depend on successful trials, regulatory approvals, manufacturing investment, and commercialization. Where Will Novo Stock Be in 10 Years?
Negative Sentiment: Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates. These concerns help explain why the stock remains under pressure despite the promising CagriSema results. How Investors May Respond To Novo Nordisk Obesity Drug Competition

Analysts Set New Price Targets

Several research analysts have commented on the stock. Cfra lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective for the company. in a report on Tuesday, September 22nd. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, September 29th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Friday, October 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $59.44.

Check Out Our Latest Report on NVO

Novo Nordisk A/S Stock Performance

NVO opened at $39.10 on Thursday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company’s 50 day moving average is $42.21 and its 200 day moving average is $44.01. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The company has a market cap of $174.58 billion, a price-to-earnings ratio of 9.56, a PEG ratio of 1.34 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is 20.05%.

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.